Barbara Belletti Selected Research

Stathmin

5/2022	HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.
1/2019	Stathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis.
10/2016	p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.
1/2014	Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo.
5/2013	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.
1/2012	Stathmin is dispensable for tumor onset in mice.
11/2011	Stathmin: a protein with many tasks. New biomarker and potential target in cancer.
5/2008	Stathmin activity influences sarcoma cell shape, motility, and metastatic potential.
1/2005	p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Belletti Research Topics

Disease

30	Neoplasms (Cancer) 01/2022 - 01/2004
18	Breast Neoplasms (Breast Cancer) 05/2022 - 04/2003
6	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 05/2013
5	Neoplasm Metastasis (Metastasis) 05/2022 - 05/2008
5	Ovarian Epithelial Carcinoma 01/2020 - 06/2013
4	Carcinogenesis 01/2019 - 01/2012
4	Carcinoma (Carcinomatosis) 01/2019 - 04/2003
3	Disease Progression 01/2021 - 12/2019
3	Inflammation (Inflammations) 01/2016 - 01/2004
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 07/2017
2	Wounds and Injuries (Trauma) 08/2014 - 05/2014
2	Surgical Wound 05/2014 - 03/2008
2	Sarcoma (Soft Tissue Sarcoma) 05/2008 - 01/2005
1	Triple Negative Breast Neoplasms 05/2022
1	Colorectal Neoplasms (Colorectal Cancer) 10/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2018
1	Genomic Instability 01/2017
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2014
1	Papilloma (Papillomatosis) 01/2012
1	Glioblastoma (Glioblastoma Multiforme) 05/2008
1	Colonic Neoplasms (Colon Cancer) 01/2004
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2004
1	Adenoma (Adenomas) 10/2003
1	Goiter 10/2003

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 05/2022 - 04/2003
9	StathminIBA 05/2022 - 01/2005
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2011
7	PlatinumIBA 01/2021 - 01/2017
4	Hormones (Hormone)IBA 01/2022 - 01/2018
4	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2017
4	Phosphotransferases (Kinase)IBA 10/2020 - 12/2013
4	Biological ProductsIBA 12/2019 - 03/2008
3	Messenger RNA (mRNA)IBA 01/2021 - 04/2003
3	MicroRNAs (MicroRNA)IBA 01/2020 - 06/2013
2	Cyclin DIBA 01/2022 - 10/2021
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2021 - 05/2010
2	Estrogen ReceptorsIBA 06/2021 - 01/2020
2	Ribosomal Proteins (Ribosomal Protein)IBA 01/2016 - 05/2014
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 01/2016 - 05/2014
2	CarcinogensIBA 01/2012 - 03/2007
2	CyclinsIBA 03/2011 - 05/2010
1	ChromatinIBA 05/2022
1	palbociclibIBA 10/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Sp1 Transcription FactorIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Cetuximab (Erbitux)FDA Link 01/2021
1	GlucocorticoidsIBA 10/2020
1	Glutamine (L-Glutamine)FDA Link 01/2020
1	human ERBB2 proteinIBA 01/2020
1	RNA Splicing FactorsIBA 01/2020
1	PTB-Associated Splicing FactorIBA 01/2020
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	LigandsIBA 01/2020
1	Proline (L-Proline)FDA Link 01/2020
1	Glu Transfer RNAIBA 12/2019
1	ErbB Receptors (EGF Receptor)IBA 12/2019
1	NucleolinIBA 12/2019
1	Ubiquitin-Specific ProteasesIBA 01/2019
1	Cyclin-Dependent Kinase Inhibitor p27IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2016
1	dacomitinibIBA 10/2016
1	Protein Isoforms (Isoforms)IBA 10/2016
1	Lapatinib (GW572016)FDA Link 10/2016
1	saracatinibIBA 10/2016
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 10/2016
1	STAT Transcription FactorsIBA 08/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2014
1	CytokinesIBA 08/2014
1	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 08/2014
1	sanguinarineIBA 08/2014
1	Apoptosis Regulatory ProteinsIBA 05/2014
1	Indicators and Reagents (Reagents)IBA 05/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013
1	3-methylcholanthryleneIBA 01/2012
1	NitrosaminesIBA 01/2012
1	Tumor Viral Antigens (Large T Antigen)IBA 01/2012
1	Acetates (Acetic Acid Esters)FDA Link 01/2012
1	DNA (Deoxyribonucleic Acid)IBA 10/2005
1	Oxygen (Dioxygen)IBA 01/2004
1	Oxidants (Oxidizing Agents)IBA 01/2004
1	DemulcentsIBA 01/2004
1	AntioxidantsIBA 01/2004
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2004
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2004
1	Cyclin D3IBA 10/2003
1	BRCA1 ProteinIBA 04/2003

Therapy/Procedure

15	Therapeutics 01/2021 - 05/2008
6	Drug Therapy (Chemotherapy) 01/2021 - 06/2013
2	Radiotherapy 01/2021 - 03/2008
1	Oral Administration 08/2014
1	Segmental Mastectomy (Lumpectomy) 03/2008